Repligen Corporation (RGEN)
NASDAQ: RGEN · Real-Time Price · USD
113.54
-5.97 (-5.00%)
At close: Sep 12, 2025, 4:00 PM EDT
115.00
+1.46 (1.29%)
After-hours: Sep 12, 2025, 7:59 PM EDT

Company Description

Repligen Corporation, a life sciences company, develops and commercializes bioprocessing technologies and systems in North America, Europe, the Asia Pacific, and internationally.

It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.

The company also provides chromatography products, including OPUS pre-packed chromatography columns, which are used in the purification of biologics; and OPUS smaller-scale columns that are used in the high throughput process development screening, viral clearance validation studies, and scale down validation of chromatography processes, as well as ELISA test kits.

In addition, it offers filtration products, such as XCell ATF Cell Retention Systems that are filtration devices used in upstream perfusion and cell culture processing; TangenX flat sheet cassettes, which are used in downstream biologic drug concentration, buffer exchange, and formulation processes; KrosFlo tangential flow filtration and tangential flow depth filtration systems; and ProConnex TFDF flow paths.

Further, it provides process analytics products, such as slope spectroscopy systems under the SoloVPE, FlowVPE, and FlowVPX brands.

The company sells its products to life sciences, biopharmaceutical, and diagnostics companies; laboratory researchers; and contract manufacturing organizations.

Repligen Corporation has a collaboration agreement with Navigo Proteins GmbH to develop multiple affinity ligands.

The company was incorporated in 1981 and is headquartered in Waltham, Massachusetts.

Repligen Corporation
Repligen logo
CountryUnited States
Founded1981
IndustryMedical Instruments & Supplies
SectorHealthcare
Employees1,778
CEOOlivier Loeillot

Contact Details

Address:
Building 1, Suite 100
Waltham, Massachusetts 02453
United States
Phone781 250 0111
Websiterepligen.com

Stock Details

Ticker SymbolRGEN
ExchangeNASDAQ
Stock TypeCommon Stock
Fiscal YearJanuary - December
Reporting CurrencyUSD
CIK Code0000730272
CUSIP Number759916109
ISIN NumberUS7599161095
Employer ID04-2729386
SIC Code2836

Key Executives

NamePosition
Olivier LoeillotPresident, Chief Executive Officer and Director
Anthony J. HuntExecutive Chair
Jason K. GarlandChief Financial Officer and Chief Compliance Officer
James R. BylundChief Operating Officer
Ralf KuriyelSenior Vice President of Research and Development

Latest SEC Filings

DateTypeTitle
Sep 10, 2025144Filing
Sep 8, 2025SCHEDULE 13G/AFiling
Sep 2, 20258-KCurrent Report
Aug 7, 202510-QQuarterly Report
Jul 29, 20258-KCurrent Report
May 15, 20258-KCurrent Report
May 15, 2025144Filing
Apr 29, 202510-QQuarterly Report
Apr 29, 20258-KCurrent Report
Apr 24, 2025SCHEDULE 13G/AFiling